Literature DB >> 10987220

Axillary surgery in breast cancer management--background, incidence and extent of nodal spread, extent of surgery and accurate axillary staging, surgical procedures.

M Blichert-Toft1.   

Abstract

The prime objectives of axillary surgery in the management of breast cancer are 1) accurate staging, 2) treatment to cure and 3) quantitative information of metastatic lymph nodes for prognostic purposes and allocation to adjuvant protocols. It is generally agreed that axillary node status in potentially curable breast cancer is considered the single best predictor of outcome and the main determinant of allocation to adjuvant therapy. No physical examination, no imaging techniques, and no molecular biologic markers can today replace axillary surgery for staging purposes. The objectives of axillary surgery are best obtained by carrying out a complete axillary clearance. Nonetheless, less radical surgery is generally performed by carrying out a sampling procedure with a yield of about 4 nodes or a partial axillary dissection level I-II with at least 10 nodes recovered. Understaging the axilla is detrimental to outcome and, furthermore, locoregional tumor control is important for survival. Axillary surgery should therefore be conducted in accordance with high professional standards.

Entities:  

Mesh:

Year:  2000        PMID: 10987220     DOI: 10.1080/028418600750013005

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  2 in total

1.  Lymph node ratio is more valuable than level III involvement for prediction of outcome in node-positive breast carcinoma patients.

Authors:  Emin Yildirim; Ugur Berberoglu
Journal:  World J Surg       Date:  2007-02       Impact factor: 3.352

2.  The axillary nodal harvest in breast cancer surgery is unchanged by sentinel node biopsy or the timing of surgery.

Authors:  B E Byrne; R I Cutress; J Gill; M H Wise; C Yiangou; A Agrawal
Journal:  Int J Breast Cancer       Date:  2012-05-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.